Skip to main content

Table 2 TILs distribution according to tumor subtype and clinical characteristics

From: Immune characterization of breast cancer metastases: prognostic implications

 

TILs %, median (Q1 – Q3): all patients 5 (2–10)

Overall

p value

TN

p value

HER2+

p value

Tumor phenotype

 TN

5 (2–10)

 

–

 

–

 

 HER2+

5 (2–11)

0.855

–

–

–

–

Age at BC diagnosis

  ≤ 50 years

3 (2–8)

0.002

3 (2–10)

0.037

4 (2–8)

0.010

  > 50 years

8 (5–15)

7 (4–11)

9 (5–18)

HR status

 Negative

–

–

–

–

9 (5–15)

0.029

 Positive

–

–

4 (2–8)

Organ/site of biopsy

Liver

5 (2–8)

0.277

5 (5–11)

0.936

5 (2–8)

0.119

Skin

3(2–10)

3 (2–10)

4 (2–10)

Lung

9 (5–18)

8 (3–10)

18 (6–19)

CNS

6 (3–11)

4 (3–38)

11 (5–11)

Other

5 (2–8)

5 (2–19)

5 (2–8)

Pre-biopsy systemic treatment for MBC

 No

5 (3–11)

0.563

5 (3–10)

0.104

4 (2–13)

0.652

 Yes

5 (2–8)

2 (2–5)

6 (5–9)

  1. Abbreviations: TILs tumor-infiltrating lymphocytes, Q1 first quartile, Q3 third quartile, p p value, significant values in bold, TN triple negative, HER2 human epidermal growth factor receptor-2, BC breast cancer, HR hormone receptor, CNS central nervous system, MBC metastatic breast cancer